FDA Seems Set To Label Eylea For Retinopathy Of Prematurity Despite Failed Primary Endpoint
Executive Summary
Two studies failed to demonstrate that Eylea was non-inferior to laser treatment. Agency says compared to the expected natural history, there is a ‘clear beneficial effect’ of Eylea which also maintains peripheral vision. Advisory committee to discuss how to convey findings in label.